Human IgG4 Antibody |
48305-100ul |
SAB |
100ul |
EUR 399.6 |
Human Antibody Laboratories manufactures the anti human igg4 antibody reagents distributed by Genprice. The Anti Human Igg4 Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact human Antibody. Other Anti products are available in stock. Specificity: Anti Category: Human Group: Igg4 Antibody
Human IgG4 Antibody |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
Human IgG4 Antibody |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
Human IgG4 Antibody |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
Human IgG4 Antibody |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
Human IgG4 Antibody |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
Human IgG4 Antibody |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells. |
IgG4 Antibody |
SAB |
100ul |
EUR 399.6 |
Igg4 Antibody information
Human IgG4 Fc Antibody |
R20191-100UG |
NSJ Bioreagents |
100ug |
EUR 347.65 |
Description: This recombinant Human IgG4 Fc antibody reacts to the Fc region of hIgG4. No cross reactivity with human IgG1, IgG2, IgG3, IgM, IgA, IgD, IgE, mouse/rat/goat IgG. |
Human IgG4 Fc Antibody |
R20191BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 347.65 |
Description: This recombinant Human IgG4 Fc antibody reacts to the Fc region of human IgG4. No cross reactivity with human IgG1, IgG2, IgG3, IgM, IgA, IgD, IgE, mouse IgG, rat IgG, or goat IgG. |
Human IgG4 Fc Antibody |
R20191SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 832.15 |
Description: This recombinant Human IgG4 Fc antibody reacts to the Fc region of hIgG4. No cross reactivity with human IgG1, IgG2, IgG3, IgM, IgA, IgD, IgE, mouse/rat/goat IgG. |
Anti-PD-1 (Sintilimab), Human IgG4 Antibody |
A2156-100 |
Biovision |
100 µg |
EUR 612 |
Anti-TNF alpha (Humicade), Human IgG4 Antibody |
A1093-200 |
Biovision |
each |
EUR 874.8 |
Anti-IL-4Rα (Dupilumab), Human IgG4 Antibody |
A2148-100 |
Biovision |
100 µg |
EUR 612 |
Mouse anti-Human IgG4 Antibody |
abx401164-05mg |
Abbexa |
0.5 mg |
EUR 794.4 |
|
Mouse anti-Human IgG4 Antibody |
abx401328-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Mouse Anti-Human IgG4 antibody |
STJ99557-100l |
St John's Laboratory |
100 µl |
EUR 214.8 |
Description: Unconjugated Mouse monoclonal to Human IgG4 antibody |
Mouse Anti-Human IgG4 antibody |
STJ99557-1mL |
St John's Laboratory |
1 mL |
EUR 1438.8 |
Description: Unconjugated Mouse monoclonal to Human IgG4 antibody |
Human IgG4 Conjugated Antibody |
C48305 |
SAB |
100ul |
EUR 476.4 |
Mouse Anti-Human IgG4 (Fc) Antibody |
abx023364-5mg |
Abbexa |
5 mg |
EUR 2631.6 |
|
Mouse Anti-Human IgG4 (Fc) Antibody |
abx023387-1mg |
Abbexa |
1 mg |
EUR 718.8 |
|
Mouse Anti-Human IgG4 antibody (AU) |
STJ99395-100l |
St John's Laboratory |
100 µl |
EUR 116.4 |
Description: AU conjugated Mouse monoclonal to Human IgG4 |
Mouse Anti-Human IgG4 antibody (AU) |
STJ99395-1mL |
St John's Laboratory |
1 mL |
EUR 560.4 |
Description: AU conjugated Mouse monoclonal to Human IgG4 |